- Symposium Builds on Philips' Support for SAVE Study
Examining Impact of Obstructive Sleep Apnea Treatment on
Cardiovascular Disease
ANDOVER, Massachusetts,
Aug. 31, 2014 /PRNewswire/ -- At this
week's European Society of Cardiology (ESC) Congress 2014, Royal
Philips (NYSE: PHG AEX: PHIA) is sponsoring a key Satellite
Symposia focused on managing patients with the complex combination
of cardiovascular disease and sleep apnea. This session builds on
Philips' ongoing support for the Sleep Apnea cardioVascular
Endpoints (SAVE) study, which launched in 2008 with the goal of
determining the effects of nasal continuous positive airway
pressure (CPAP) in preventing heart attack, stroke or heart failure
in high-risk patients with moderate to severe obstructive sleep
apnea (OSA).
Logo -
http://photos.prnewswire.com/prnh/20140122/NE50581LOGO
Ongoing Management of the Complex Patient with Cardiovascular
Disease and Apnea: Interactive Case Discussions
August 31 from 1:00 - 1:45 p.m., Vilnius Room, Village 9
Speakers: Dr. Dirk Skowasch,
University of Bonn, Germany; and,
Dr. Frederic Roche, Saint-Etienne
University Hospital, France
Professor Dirk Skowasch of the
University of Bonn, Germany, will
initiate the session by focusing on the rationale for treating
sleep disordered breathing in cardiovascular disease patients. Dr.
Frederic Roche of Saint-Etienne
University Hospital, France, will
continue the discussion by providing an overview of the challenges
physicians face regarding this complex patient management. The
session will wrap up with interactive case discussions of patients
with co-morbidities and sleep disordered breathing.
"Obstructive sleep apnea (OSA), which affects nearly 100 million
individuals worldwide, is associated with an increased risk for
cardiovascular disease and death, but there are few studies
examining the beneficial effects of therapy on this disorder," said
Teofilo Lee-Chiong, MD and Chief
Medical Liaison for Philips. "The Symposia at the ESC Congress 2014
will contribute important insights into treatment of these
patients."
The SAVE study reached a major milestone in February 2014 as it achieved its enrollment goal
of 2,500 patients, making it the largest global sleep apnea
clinical trial performed that reaches across seven countries and 84
hospitals and medical institutions. Now that the study has
completed enrollment, the study investigators will continue to
evaluate the participants over the next two years. If the results
of this study prove positive, the causal relationship between OSA
and cardiovascular disease will be proven, and clinical practices
and treatment approaches to both OSA and cardiovascular disease
will be improved.
In addition to being the lead sponsor of the study, Philips also
maintains an active role in training the various SAVE sites in
positive airway pressure (PAP) adherence techniques to ensure
strong patient engagement.
For more information on Philips' presence at the ESC Congress
2014 in Barcelona, please go to
http://www.philips.com/esc and visit the Philips Booth #F500.
Follow the #ESCcongress conversation @PhilipsHealth and continue
the conversation via Philips LinkedIn Innovations in Cardiology
Group.
For more information, please contact:
Kathy O'Reilly
Philips Healthcare
Tel: +1 978-659-2638
Mobile: +1 978-221-8919
E-mail: Kathy.oreilly@philips.com
Twitter: @kathyoreilly
About Royal Philips:
Royal Philips (NYSE: PHG, AEX:
PHIA) is a diversified health and well-being company, focused on
improving people's lives through meaningful innovation in the areas
of Healthcare, Consumer Lifestyle and Lighting. Headquartered in
the Netherlands, Philips posted
2013 sales of EUR 23.3 billion and
employs approximately 113,000 employees with sales and services in
more than 100 countries. The company is a leader in cardiac care,
acute care and home healthcare, energy efficient lighting solutions
and new lighting applications, as well as male shaving and grooming
and oral healthcare. News from Philips is located at
www.philips.com/newscenter.